# Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

> **NCT06167317** · PHASE1 · RECRUITING · sponsor: **Gilead Sciences** · enrollment: 254 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** GS-0201
- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT06167317
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-09
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 254 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06167317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06167317, "Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06167317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*